Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Vertex Pharmaceutic (VRTX)

Vertex Pharmaceutic (VRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 80,934,672
  • Shares Outstanding, K 256,691
  • Annual Sales, $ 7,574 M
  • Annual Income, $ 2,342 M
  • 60-Month Beta 0.44
  • Price/Sales 10.61
  • Price/Cash Flow 24.77
  • Price/Book 6.17
Trade VRTX with:

Options Overview Details

View History
  • Implied Volatility 27.47% ( -2.17%)
  • Historical Volatility 40.56%
  • IV Percentile 4%
  • IV Rank 10.74%
  • IV High 52.89% on 02/01/22
  • IV Low 24.41% on 11/09/22
  • Put/Call Vol Ratio 0.52
  • Today's Volume 2,993
  • Volume Avg (30-Day) 2,174
  • Put/Call OI Ratio 0.86
  • Today's Open Interest 40,067
  • Open Int (30-Day) 39,887

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate 3.13
  • Number of Estimates 10
  • High Estimate 3.55
  • Low Estimate 2.29
  • Prior Year 3.18
  • Growth Rate Est. (year over year) -1.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
288.83 +9.16%
on 11/11/22
323.61 -2.57%
on 11/23/22
+1.41 (+0.45%)
since 10/28/22
3-Month
276.57 +14.00%
on 09/26/22
323.61 -2.57%
on 11/23/22
+33.62 (+11.94%)
since 08/26/22
52-Week
185.46 +70.01%
on 11/29/21
323.61 -2.57%
on 11/23/22
+131.71 (+71.74%)
since 11/26/21

Most Recent Stories

More News
2 Stocks Near 52-Week Highs That Could Climb Higher

This pair of stocks are bucking the trend and they could climb even higher.

CRSP : 53.34 (-3.00%)
ESALY : 65.1000 (-4.41%)
BIIB : 291.90 (-4.34%)
VRTX : 315.30 (+0.74%)
Cathie Wood Is Selling This High-Flying Stock. Here's Why You Should Buy It Instead

The ARK Invest founder might regret trimming her position in this biotech stock.

ARKG : 30.63 (-3.38%)
VRTX : 315.30 (+0.74%)
CRSP : 53.34 (-3.00%)
BioMarin (BMRN) Up After FDA Scraps AdCom Meet for BLA Filing

The FDA decides not to hold an advisory committee meeting for BioMarin Pharmaceuticals' (BMRN) regulatory filing seeking approval for hemophilia A gene therapy, valrox.

BMRN : 98.66 (+1.80%)
VRTX : 315.30 (+0.74%)
ANGN : 0.8785 (-2.39%)
CELU : 1.6300 (+3.82%)
AbbVie's (ABBV) Skyrizi Gets EU Nod for Crohn's Disease

AbbVie's (ABBV) Skyrizi becomes the first specific IL-23 inhibitor to get approval for Crohn's disease in the European Union.

MRK : 108.45 (+0.88%)
GILD : 85.21 (-1.22%)
VRTX : 315.30 (+0.74%)
ABBV : 158.43 (-0.75%)
2 Stocks to Buy That Will Grow Your Money Over Time

Cooling inflation is raising hopes of a slower pace of rate hikes ahead. Moreover, experts now see chances of the economy avoiding a recession. Hence, investors could consider buying quality stocks, Comcast...

CMCSA : 35.59 (-0.17%)
VRTX : 315.30 (+0.74%)
Is This Biotech Stock a Buy for Under $3?

Biotech company Bionano Genomics (BNGO) has beaten analysts’ top-line estimate in the third quarter. However, its cash and cash equivalents balance has declined year-over-year. Therefore, is it a buy...

AMGN : 282.62 (-0.39%)
BNGO : 2.04 (-8.11%)
OTSKY : 16.9800 (-0.18%)
UTHR : 270.69 (+0.98%)
VRTX : 315.30 (+0.74%)
Merck (MRK) Keytruda Advanced Gastric Cancer Study Meets Goal

Top-line data from a late-stage study shows that Merck's (MRK) Keytruda combined with chemotherapy improved overall survival in patients with advanced gastric cancer.

BMY : 79.14 (-0.13%)
MRK : 108.45 (+0.88%)
VRTX : 315.30 (+0.74%)
ANGN : 0.8785 (-2.39%)
GSK to Withdraw Blenrep From U.S. Market on FDA Request

GSK, at the request of the FDA, is set to withdraw the U.S. marketing authorization for Blenrep. The FDA's request comes after the failure of a phase III confirmatory study, DREAMM-3.

GSK : 33.76 (-0.68%)
MRK : 108.45 (+0.88%)
GILD : 85.21 (-1.22%)
VRTX : 315.30 (+0.74%)
Should iShares MSCI USA Min Vol Factor ETF (USMV) Be on Your Investing Radar?

Style Box ETF report for USMV

USMV : 73.54 (-1.09%)
VRTX : 315.30 (+0.74%)
RSG : 136.52 (-0.26%)
SPY : 395.91 (-1.60%)
TMUS : 149.90 (-0.76%)
IVV : 397.69 (-1.58%)
The 5 Best Stocks to Invest in for the Long Term

Despite current market uncertainties, the U.S. economy's long-term growth prospects are pretty viable. Experts believe inflation will fall dramatically in the coming year, and robust growth will follow....

A : 152.30 (-2.97%)
CNC : 84.93 (+0.08%)
MSFT : 241.76 (-2.32%)
MYE : 22.45 (-0.18%)
VRTX : 315.30 (+0.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which...

See More

Key Turning Points

3rd Resistance Point 327.07
2nd Resistance Point 324.00
1st Resistance Point 319.65
Last Price 315.30
1st Support Level 312.23
2nd Support Level 309.16
3rd Support Level 304.81

See More

52-Week High 323.61
Last Price 315.30
Fibonacci 61.8% 270.84
Fibonacci 50% 254.54
Fibonacci 38.2% 238.23
52-Week Low 185.46

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar